Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | THRB | P10828 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 6/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CETP | P11597 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23411303 | 1.00 | SMN1; SMN2 (0.47) | SMN1; SMN2THRBGAAGPR119LMNA | |
| SCHEMBL23411388 | 0.93 | SMN1; SMN2 (0.47) | SMN1; SMN2THRBGAAGPR119LMNA | |
| SCHEMBL25167085 | 0.87 | LMNA (0.47) | SMN1; SMN2THRBLMNATP53MAPT | |
| SCHEMBL23411137 | 0.82 | GPR119 (0.48) | SMN1; SMN2THRBGAAGPR119LMNA | |
| SCHEMBL29967084 | 0.82 | GPR119 (0.48) | SMN1; SMN2THRBGAAGPR119LMNA | |
| SCHEMBL29891575 | 0.82 | GPR119 (0.48) | SMN1; SMN2THRBGAAGPR119LMNA | |
| SCHEMBL14157426 | 0.82 | GPR119 (0.48) | SMN1; SMN2THRBGAAGPR119LMNA | |
| SCHEMBL14707043 | 0.80 | TP53 (0.48) | SMN1; SMN2THRBGAAGPR119LMNA | |
| SCHEMBL23411168 | 0.80 | GPR119 (0.46) | SMN1; SMN2THRBGAAGPR119LMNA | |
| SCHEMBL29967140 | 0.80 | GPR119 (0.46) | SMN1; SMN2THRBGAAGPR119LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2025-11-25 | — | — | US | disclosed |
| EP-4065574-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | Bayer Aktiengesellschaft (DE) | 2022-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DGKK, DGKG, DGKA | SMN1; SMN2 4657/4885THRB 3233/4885GAA 1133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.